

Effect of a diet of healthy food or a Mediterranean diet on change in the composition and function of faecal microbiota

Submission date 28/03/2017	Recruitment status No longer recruiting	☐ Prospectively registered
		☐ Protocol
Registration date 07/04/2017	Overall study status Completed	☐ Statistical analysis plan
		☒ Results
Last Edited 07/06/2023	Condition category Nutritional, Metabolic, Endocrine	☐ Individual participant data

Plain English summary of protocol

Current plain English summary as of 20/04/2021:

Background and study aims

Metabolic syndrome is a term used to describe a combination of factors which increase a person's risk of heart disease and other health problems, such as diabetes and stroke. Many of these factors are linked with obesity, such as high blood pressure, cholesterol and body fat. Recent research has shown that there may be a link between the composition of different bacteria that live in the gut (gut microbiota) and the biological processes of disease. In a previous study, it was found that a Mediterranean diet, supplemented with nuts, led to a major reduction in disease risk factors. The aim of this study is to look at two different diets to find out what effect they have on the composition of bacteria in the gut and metabolic risk factors.

Who can participate?

Overweight obese men and women aged 30-65 ,with Metabolic Syndrome.

What does the study involve?

Participants are randomly allocated to two different interventions in a random order. Each of the intervention periods will last for eight weeks, and there is a four week period of consuming thier habitual diet in between them, to ensure the results of the different interventions do not influence each other. The first intervention involves eating 50g of nuts every day in addition to the regular non-Mediterranean diet. The second intervention involves eating a Mediterranean diet, with high consumption of vegetables and olive oil and moderate consumption of protein. Before and after each dietary period, participants provide stool and blood samples which are then examined to assess the composition of bacteria living in the gut and to see if there has been any change to metabolic syndrome risk factors.

What are the possible benefits and risks of participating?

Participants may benefit from following a healthier dietary patterns with demonstrated benefits on cardiometabolic health. There is a small risk of pain or bruising when blood samples are collected.

Where is the study run from?

1. Rovira i Virgili University (Spain)
2. Hospital Universitari Sant Joan (Spain)
3. Primary Care Centers from the Catalan Institute of Health

When is the study starting and how long is it expected to run for?

January 2017 to December 2019

Who is funding the study?

Instituto de Salud Carlos III (Spain)

Who is the main contact?

Dr Mònica Bulló Bonet

monica.bullo@urv.cat

Previous plain English summary:

Background and study aims

Metabolic syndrome is a term used to describe a combination of factors which increase a person's risk of heart disease and other health problems, such as diabetes and stroke. Many of these factors are linked with obesity, such as high blood pressure, cholesterol and body fat. Recent research has shown that there may be a link between the composition of different bacteria that live in the gut (gut microbiota) and the biological processes of disease. In a previous study, it was found that a Mediterranean diet, supplemented with nuts, led to a major reduction in disease risk factors. The aim of this study is to look at two different diets to find out what effect they have on the composition of bacteria in the gut and on metabolic risk factors.

Who can participate?

Men and women aged 30-65 who have three or more signs of metabolic syndrome

What does the study involve?

Participants are randomly allocated to consume two diets in a random order. Each of the diets lasts for eight weeks, and there is a four week period of consuming a normal diet in between them, to ensure the results of the different diets don't influence each other. The first diet involves eating 50g of nuts every day in addition to regular diet. The second diet involves eating a Mediterranean diet, which involves high consumption of vegetables and olive oil and moderate consumption of protein. Before and after each dietary period, participants provide stool and blood samples which are then examined to assess the composition of bacteria living in the gut and to see if there has been any change to metabolic syndrome risk factors.

What are the possible benefits and risks of participating?

Participants may benefit from taking part due to the well founded benefits of consuming nuts and following a Mediterranean diet. There is a small risk of pain or bruising when blood samples are collected.

Where is the study run from?

1. Rovira i Virgili University (Spain)
2. Hospital Universitari Sant Joan (Spain)

When is the study starting and how long is it expected to run for?

January 2017 to December 2019

Who is funding the study?
Instituto de Salud Carlos III (Spain)

Who is the main contact?
Dr Mònica Bulló Bonet
monica.bullo@urv.cat

Contact information

Type(s)
Scientific

Contact name
Dr Mònica Bulló Bonet

ORCID ID
<https://orcid.org/0000-0002-0218-7046>

Contact details
Unitat de Nutrició Humana
Universitat Rovira i Virgili (URV)
C/Sant Llorenç, 21
Reus
Spain
43201
+34 977 75 93 13
monica.bullo@urv.cat

Additional identifiers

Protocol serial number
PI/00516

Study information

Scientific Title
Effect of a diet on healthy food or a Mediterranean diet on change in the composition and function of faecal microbiota and its relationship with the metabolic improvement

Acronym
METADIET

Study objectives
Current study hypothesis as of 20/04/2021:
The consumption of certain foods typical of the Mediterranean diet in the context of a non-Mediterranean diet will modify the composition and functionality of the intestinal microbiota towards a healthier profile and this will be associated with a metabolic improvement.

Previous study hypothesis:
The consumption of certain foods typical of the Mediterranean diet in the context of a non-

Mediterranean diet will modify the composition and functionality of the intestinal microbiota towards a healthier profile.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Committee (Hospital Universitari Sant Joan; Reus), 26/01/2017, Ref. CEIm: 04/2017

Study design

Randomised cross over trial

Primary study design

Interventional

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Obesity and metabolic syndrome

Interventions

Participants are randomised to consume two dietary interventions in a random order. Each intervention period lasts for a total of eight weeks, with a four week wash out period between them.

Diet one: Participants consume their regular diet (RD) with the addition of 50g of nuts/day.

Diet two: Participants consume the Mediterranean diet. This consists of high consumption of vegetables and olive oil and moderate consumption of protein.

Participants will be followed up before and after each intervention period. Classic metabolic risk markers will be analyzed (glucose, lipid profile) as well as inflammation, oxidation and endothelial function markers by routine methods. The taxonomic composition in faeces will be determined as well as a quantitative metagenomic analysis in one sub-group. For the metabolomic analysis in plasma and faeces samples it will be use different analytic platforms according to the sample.

Intervention Type

Behavioural

Primary outcome(s)

Current primary outcome measure as of 09/12/2020:

Faecal microbiota is assessed through measuring the taxonomic composition in faeces (16S RNA) and quantitative metagenomic analysis at baseline and 8 weeks in each intervention period.

Previous primary outcome measure:

Metabolic risk markers are assessed by measuring glucose and lipid profile, inflammation, oxidation, and endothelial function markers by routine methods, ELISA and Luminex platform at baseline and 8 weeks in each intervention period.

Key secondary outcome(s))

Current secondary outcome measures as of 09/12/2020:

Metabolic risk markers are assessed by measuring glucose and lipid profile, inflammation, oxidation, and endothelial function markers by routine methods, ELISA and Luminex platform at baseline and 8 weeks in each intervention period.

Previous secondary outcome measures:

Faecal microbiota is assessed through measuring the taxonomic composition in faeces (16S RNA) and quantitative metagenomic analysis at baseline and 8 weeks in each intervention period.

Completion date

31/12/2019

Eligibility

Key inclusion criteria

Current inclusion criteria as of 20/04/2021:

1. Men and women
2. 30-60 years old - updated 17/10/2018: 30-65 years old
3. BMI ≥ 25 and < 35 kg/m²
4. ≥ 3 Metabolic Syndrome criteria according to the ATP III harmonised criteria (doi: 10.1016/j.amjcard.2006.08.045)
 - 4.1. Hypertension or hypertension treatment
 - 4.2. Altered glycemia (≥ 100 mg/dl) or treatment
 - 4.3. HDL cholesterol (men < 40 mg/dl or women < 50 mg/dl) or treatment
 - 4.4. Altered triglycerides (≥ 150 mg/dl) or treatment
 - 4.5. Abnormal waist circumference (men ≥ 102 cm or women ≥ 88)
5. Following a non-Mediterranean Diet (scoring ≤ 9 in the 17-items MedDiet score used in the PREDIMED-Plus intervention trial) (questionnaire available at doi: 10.1093/ije/dyy225)

Previous inclusion criteria:

1. Men and women
2. 30-60 years old - updated 17/10/2018: 30-65 years old
3. BMI ≥ 25 and < 35
4. ≥ 3 Metabolic Syndrome criteria:
 - 4.1. Hypertension or hypertension treatment
 - 4.2. Altered glycemia (≥ 100 mg/dl)
 - 4.3. HDL cholesterol (men < 40 mg/dl or women < 50 mg/dl)
 - 4.4. Altered triglycerides (≥ 150 mg/dl)
 - 4.5. Abnormal waist circumference (men ≥ 102 cm or women ≥ 88)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

44

Key exclusion criteria

Current inclusion criteria as of 20/04/2021:

1. BMI<25kg/m² or BMI≥35
2. Type 2 diabetes
3. Secondary obesity or related pathologies
4. Non-controlled hypertension (Systolic arterial pressure (SAP)>159mmHg; Diastolic arterial pressure (DAP)>99mmHg)
5. LDL cholesterol >160mg/dl
6. Tryglicerides >400mg/dl
7. Mediterranean adscription punctuation >9 (17-items MedDiet PREDIMED Plus questionnaire)
8. Frequent nuts consumption (≥90g/week)
9. Different chronic diseases (inflammatory, infectious, chronic obstructive pulmonary, neoplasias, endocrine, or hematological diseases)
10. Leucocytosis (leucocytes >11×10⁹)
11. Pharmacological treatment (anti-inflammatory, corticoids, hormones or antibiotics)
12. Changes of hypertension or lipidic profile medication (last 3 months).
13. Body weight loss (>5kg in the last 3 months).
14. Lost weight medication changes (last 3 months).
15. Breeding or pregnancy.
16. Diseases history (hepatic cirrhosis, intestinal inflammatory, intestinal resection).
17. Nuts allergy.
18. Probiotics, prebiotics or laxatives consumption

Previous exclusion criteria:

1. BMI<25kg/m² or BMI≥35
2. Type 2 diabetes
3. Secondary obesity or related pathologies
4. Non-controlled hypertension (Systolic arterial pressure (SAP)>159mmHg; Diastolic arterial pressure (DAP)>99mmHg)
5. LDL cholesterol >160mg/dl
6. Tryglicerides >400mg/dl
7. Mediterranean adscription punctuation ≥7 (PREDIMED trial)
8. Frequent nuts consumption (≥90g/week)
9. Frequent legumes consumption (≥120g/week)
10. Different chronic diseases (inflammatory, infectious, chronic obstructive pulmonary, neoplasias, endocrine, or hematological diseases)
11. Leucocytosis (leucocytes >11×10⁹)
12. Pharmacological treatment (anti-inflammatory, corticoids, hormones or antibiotics)
13. Changes of diabetes, hypertension or lipidic profile medication (last 3 months).
14. Body weight loss (>5kg in the last 3 months).
15. Lost weight medication changes (last 3 months).
16. Breeding or pregnancy.

- 17. Diseases history (hepatic cirrhosis, intestinal inflammatory, intestinal resection).
- 18. Nuts or legumes allergy.
- 19. Probiotics, prebiotics or laxatives consumption

Date of first enrolment

16/02/2017

Date of final enrolment

09/07/2018

Locations

Countries of recruitment

Spain

Study participating centre

Rovira i Virgili University (URV) / Institute of Health Pere Virgili (IISPV)

Nutrition and Metabolic Disorders Research Group

C/Sant Llorenç, 21

Reus

Spain

43201

Study participating centre

Hospital Universitari Sant Joan (HUSJ)

Av/del Dr. Josep Laporte, 2

Reus

Spain

43204

Study participating centre

Primary Care Centers-Catalan Institute of Health (ICS)

Reus-Alcover-Salou

Spain

43205

Sponsor information

Organisation

Instituto de Salud Carlos III

ROR

<https://ror.org/00ca2c886>

Funder(s)

Funder type

Government

Funder Name

Instituto de Salud Carlos III

Alternative Name(s)

SaludISCI, Instituto de Salud Carlos III, Instituto de Salud Carlos III | Madrid, Spain, Carlos III Institute of Health, Institute of Health Carlos III, Carlos III Health Institute, La misión del Instituto de Salud Carlos III (ISCI), ISCI

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Spain

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Mònica Bulló Bonet (monica.bullo@urv.cat)

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/06/2021	17/06/2021	Yes	No
Other publications		29/11/2021	07/06/2023	Yes	No